It is easy to understand the mechanisms of targeting tumors with TNFR2 antagonists, and blocking TNFR2 may have the effect of killing two birds with one stone: boosting antitumor immune responses and directly killing TNFR2 overexpressing tumor cells and tumor mesenchymal cells. The gene discussed is TNFRSF1B; the disease is neoplasm.